The most common malignance of the urinary tract is urothelial cell carcinoma. The standard of care of non muscle invasive bladder cancer, intravesical chemo- and immunotherapy, while effective, is associated with a considerable side-effect profile and an elevated number of failures: approximately 30% of patients either do not respond to treatment or reveal recurrent disease within 5 years. Muscle invasive bladder cancer is life threatening, showing modest chemosensitivity, and usually requires radical cystectomy with or without neoadjuvant chemotherapy which may improve the overall survival benefit. Although bladder cancer is fairly well-genetically characterized, clinical trials with molecularly targeted agents have, in comparison to other solid tumors, been few in number and largely unsuccessful. Hence, bladder cancer represents a considerable opportunity and challenge for alternative therapies
Muscle-invasive and metastatic bladder cancer: current and emerging therapies
CARRADORI, Simone;
2013-01-01
Abstract
The most common malignance of the urinary tract is urothelial cell carcinoma. The standard of care of non muscle invasive bladder cancer, intravesical chemo- and immunotherapy, while effective, is associated with a considerable side-effect profile and an elevated number of failures: approximately 30% of patients either do not respond to treatment or reveal recurrent disease within 5 years. Muscle invasive bladder cancer is life threatening, showing modest chemosensitivity, and usually requires radical cystectomy with or without neoadjuvant chemotherapy which may improve the overall survival benefit. Although bladder cancer is fairly well-genetically characterized, clinical trials with molecularly targeted agents have, in comparison to other solid tumors, been few in number and largely unsuccessful. Hence, bladder cancer represents a considerable opportunity and challenge for alternative therapiesFile | Dimensione | Formato | |
---|---|---|---|
the urologist.pdf
Solo gestori archivio
Dimensione
241.04 kB
Formato
Adobe PDF
|
241.04 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.